Member Info for CauldStream7

Have just noticed 2 massive buys this morning at 8.82 and 8.89p. What's up? Not the price - yet.

Eva:

Now I agree. I believe the next quarter will bring positives from FDA and Bio Glucagon interim results. Plus Sol (Incanthera).
If all 3 come through maybe we'll see significant pop.

Eva:

Bankruptcy is a bit strong. Floor is lower than present. Look at end Nov 2019. The price was 7.05p one day and rose to 21p the next on the Avion announcement. Nil desperandum!

Thordon:

I agree; I've never had a problem in buying through Hargreaves Lansdown. Can't think why Mike1608 has a problem. Plenty of shares being sold so should by ample availability for buyers.

Nolupus:

The Swiss company holds Mrs Zimmer's shares in IMM - so all in the family.

Nolupus/Eva:

Nolupus, you say you are expecting a TR1 (notification of change in a major share holding) from Lanstead or Zimmer soon.
I'm no expert, but the huge amount of buying and selling that has been going on this week does not remind me of them, or certainly not Zimmer. The trades we've been seeing are evidence of traders taking advantage of pricing anomalies in IMM's shares, and they make no pretence of it. Take one lot of shares and their are several examples that I could give.
103,159 shares bought at 09:20:41 @8.7205 total cost £8996.
103,159 shares sold at 09:28:42 @8.8859 total receipt £9280. Trader's profit: £284.
Repeated over the trading day = a few thousand £s for the trader.
This may be suggestive of Lanstead's trading pattern. But I'm sure it is not of Zimmer - I don't see him as a ST trader. I expect him to hold as President and Chief Science Officer of IMM because he knows what is in the pipeline.

Eva:

Most of the first sentence got dropped somehow.
What I wrote was " This share needs news and most of us expected a positive announcement from FDA on a new P3 for Lupuzor before last Christmas at the latest. My view is that the negotiations between Avion/IMM and the FDA were not well handled.
The rest of my post follows from that.

Eva
well handled. Still, I'm betting that what most of us believed - that FDA approval for a new P3 trial of Lupuzor was nigh-on certain - will take place and be announced in a couple of months in time for the trial to start in 2H of this year.
Also this year according to Franklin, there should be positive news on Glucagon and BioAmp-B.
IMO, this ain't a good time to throw in the towel.

Eva
Lots of churning of large chunks of shares just a minute or so between several buys followed by identical amounts of sells with the later sometimes priced higher than the buys. I reckon it's the work of short-term traders. Don't know that much can be read into it as far as the long term future of IMM is concerned.
According to Tim Franklin the next news due concerns BioE study results due mid 1H 2021 on the pathway to Marketing approval mid-2022.

mike:
I have noted 19 buys@50,000 and 10 sells @50,000 in the first 2 hours of trading. Also 1 buy of 100,000 and 2 sells of 100,000. Is this a sign of shorters at work?

Eva:
I don't understand Jcreek's rant about your ramp just after your post in which you said you wouldn't be buying any more IMM at this time.
Funny kind of ramp!?
Why do so many people on this BB dislike you so much? You always seem a pretty reasonable person to me.

Eva:
I understand your reasoning. Very sensible.
I've invested £193K and still nibbling away, poco a poco. Possibly not very sensible!

Eva|:
If you believe that in the long run IMM's product pipeline is based on excellent research foundation, why not see the present low SP period as an opportunity to accumulate shares at rock bottom prices. With my limited income, that is what I have been doing for the past year or two. The unexpected extension of this period has enabled me to gather in many more shares than I though possible given my limited finances. Maybe I am a foolish optimist but I still believe that there will be a good payback for the patient investor in IMM's shares.

Eva:
You won't get any info out of Lisa Baderoon. She is very good at telling you that she will let us know if there is any news and to have a good day. She holds the view that it is not allowed for companies on AIM to issue RNS unless there is a marked change in the status of the Co., or of its research objectives/products.
As I said in the first of my 2 posts yest. if you read Tim Franklin's presentation which contains a chart of "Potential Newsflow"
there is very little big news expected this year apart from the go-ahead for the P3 Lupuzor trial and the announcement of Study Results for Glucagon and BioAmp-B in the latter part of this year. So not a lot of joy on the news front for this year. Much more positive news due next year.
Pharma research is a slow process unless you can devote big bucks to it.

Eva:

When you state that there has been no BOD purchases, you have overlooked the fact that the largest shareholder is IMM's President and Chief Science Officer, Dr Zimmer, who owns over 11% of the shares. More I think than even you own.
I don't know how true it is but someone on this bulletin board claimed that Dr Z.is the one responsible for setting up the Avion deal.

Eva:

Eva:
I don't understand why you regard FDA approval of Avion's parameters for the second Lupuzor Phase 3 trial should be regarded as a game-changer. I and others were sure that FDA approval of this new trial was certain. Why else would Avion have committed $25 milllion to it? So I believe that this view is already baked into the SP.
The real game-changer will be if this new P3 trial meets its end points and gains FDA approval. That will be HUGE and I feel fairly optimistic about it.
I also feel that with Glucagon, BioAmp B and CIDP the prospects are promising and the commercial prospects could be substantial.
So this is not a de-ramping post nor was the previous one. Its purpose was to point out that patience is required - as others have said in the past.

Shareholders should take a look at the presentation made to US Biotech Showcase last month by IMM's COO, Tim Franklin. There is plenty of interesting research going on to commercialise 4 or 5 new pharma products at the moment. But there is unlikely to be much news of them this year. Apart from the likely approval by the FDA in Q2 of the parameters for the Phase 3 trial of Lupuzor, after which there will be a year or more of a news gap about it, there should be news of the Bio Equivalence Study results for BioGlucagon in 1H of 2021 and of the BioE Study results for BioAmp B in 2H of 2021. But these are interims, with the Phase 3/Market Approvals not expected until 2H of 2022. Further news about the Proof of Concept/Phase 2 for the use of Lupuzor in the treatment of CIPD is also expected in 2H of 2022. These 3 all have very large markets.
Because of the sparcity of really big news about IMM's research outcomes I would expect the IMM SP to languish until late 2022 and then take off.
To read the presentation go to the IMM website and scroll down to Presentations for a much more detailed account of IMM's prospects and news flow for the next 2 - 3 years.
So all you LTHs, relax; any hope of a really game-changing RNS is unlikely for a while.

NO. One large sell and equal big buy. Also 2 big buys which were immediately cancelled.
Balance Zero.

Pangolin
Potential will only take you so far. It needs to produce commercial results within a measurable period of time. The longer the wait the steeper the fall in the SP. If you keep waiting you might be able to snap up IMM shares at 1p when patience runs out.